Artiva Biotherapeutics (ARTV) Operating Leases (2023 - 2026)

Artiva Biotherapeutics (ARTV) has reported Operating Leases for 4 consecutive years, with $7.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Operating Leases fell 29.59% year-over-year to $7.2 million; the TTM figure through Mar 2026 stood at $7.2 million (down 29.59% YoY), while the FY2025 annual figure was $7.9 million, down 25.42% from the prior year.
• Operating Leases fell to $7.2 million in Q1 2026 per ARTV's latest filing, from $7.9 million in the prior quarter.
• Across five years, Operating Leases topped out at $15.5 million in Q2 2024 and bottomed at $7.2 million in Q1 2026.
• Historically, Operating Leases has averaged $10.5 million across 4 years, with a median of $10.3 million in 2025.
• Annual changes were most pronounced in 2024 — Operating Leases fell 20.62% — and 2025, when it plunged 38.35%.
• Artiva Biotherapeutics' Operating Leases stood at $13.3 million in 2023, then retreated by 20.62% to $10.6 million in 2024, then slipped by 25.42% to $7.9 million in 2025, then retreated by 8.31% to $7.2 million in 2026.
• Business Quant data shows ARTV's Operating Leases at $7.2 million in Q1 2026, $7.9 million in Q4 2025, and $8.5 million in Q3 2025.